CytomX Therapeutics
CTMX
113 hedge funds and large institutions have $399M invested in CytomX Therapeutics in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 34 reducing their positions, and 14 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 34
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
2% more funds holding
Funds holding: 111 → 113 (+2)
1.73% less ownership
Funds ownership: 83.92% → 82.19% (-1.7%)
29% less capital invested
Capital invested by funds: $561M → $399M (-$162M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$17.7M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$14.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.1M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$10.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$56M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.4M |
| 4 |
DM
Deerfield Management
New York
|
-$9.4M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$6.71M |
CTMX Hedge Fund Activity: Q1 2019 in Review
113 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2019, worth a combined $399M — down 29% from $561M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CTMX positions and 14 closed out — a net gain of 2 holders — while 45 added to existing stakes and 34 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $17.7M. The largest seller was Fidelity Investments, cutting an estimated $56M.
- 113 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2019, up from 111 in Q4 2018.
- Funds reported $399M of CytomX Therapeutics stock for Q1 2019, down 29% quarter-over-quarter.
- 16 funds opened new CytomX Therapeutics positions in Q1 2019 and 14 closed out, a net change of +2 holders.
- The largest CytomX Therapeutics buyer in Q1 2019 was BVF Inc, an estimated $17.7M added.
- The largest CytomX Therapeutics seller in Q1 2019 was Fidelity Investments, an estimated $56M sold.
Based on aggregated 13F filings for Q1 2019.